Conjoint Gastroenterology Department, QIMR Berghofer Medical Research Institute, Queensland, Australia; School of Sports and Health Science, University of the Sunshine Coast, Queensland, Australia.
Conjoint Gastroenterology Department, QIMR Berghofer Medical Research Institute, Queensland, Australia.
Cell Mol Gastroenterol Hepatol. 2019;8(2):269-290. doi: 10.1016/j.jcmgh.2019.04.002. Epub 2019 Apr 5.
BACKGROUND & AIMS: Colorectal cancer is an epigenetically heterogeneous disease, however, the extent and spectrum of the CpG island methylator phenotype (CIMP) is not clear.
Genome-scale methylation and transcript expression were measured by DNA Methylation and RNA expression microarray in 216 unselected colorectal cancers, and findings were validated using The Cancer Genome Atlas 450K and RNA sequencing data. Mutations in epigenetic regulators were assessed using CIMP-subtyped Cancer Genome Atlas exomes.
CIMP-high cancers dichotomized into CIMP-H1 and CIMP-H2 based on methylation profile. KRAS mutation was associated significantly with CIMP-H2 cancers, but not CIMP-H1 cancers. Congruent with increasing methylation, there was a stepwise increase in patient age from 62 years in the CIMP-negative subgroup to 75 years in the CIMP-H1 subgroup (P < .0001). CIMP-H1 predominantly comprised consensus molecular subtype 1 cancers (70%) whereas consensus molecular subtype 3 was over-represented in the CIMP-H2 subgroup (55%). Polycomb Repressive Complex-2 (PRC2)-marked loci were subjected to significant gene body methylation in CIMP cancers (P < 1.6 × 10). We identified oncogenes susceptible to gene body methylation and Wnt pathway antagonists resistant to gene body methylation. CIMP cluster-specific mutations were observed in chromatin remodeling genes, such as in the SWItch/Sucrose Non-Fermentable and Chromodomain Helicase DNA-Binding gene families.
There are 5 clinically and molecularly distinct subgroups of colorectal cancer. We show a striking association between CIMP and age, sex, and tumor location, and identify a role for gene body methylation in the progression of serrated neoplasia. These data support our recent findings that CIMP is uncommon in young patients and that BRAF mutant polyps in young patients may have limited potential for malignant progression.
结直肠癌是一种表观遗传异质性疾病,但 CpG 岛甲基化表型(CIMP)的程度和范围尚不清楚。
通过 DNA 甲基化和 RNA 表达微阵列对 216 例未经选择的结直肠癌进行了全基因组甲基化和转录表达测量,并使用癌症基因组图谱 450K 和 RNA 测序数据进行了验证。使用 CIMP 亚型癌症基因组图谱外显子组评估了表观遗传调节剂的突变。
CIMP-高癌症根据甲基化谱分为 CIMP-H1 和 CIMP-H2。KRAS 突变与 CIMP-H2 癌症显著相关,但与 CIMP-H1 癌症无关。与甲基化增加一致,CIMP 阴性亚组的患者年龄从 62 岁逐步增加到 CIMP-H1 亚组的 75 岁(P<.0001)。CIMP-H1 主要由共识分子亚型 1 癌症(70%)组成,而共识分子亚型 3 在 CIMP-H2 亚组中过度表达(55%)。多梳抑制复合物 2(PRC2)标记的基因座在 CIMP 癌症中发生显著的基因体甲基化(P<1.6×10)。我们确定了易受基因体甲基化影响的致癌基因和对基因体甲基化有抗性的 Wnt 通路拮抗剂。在染色质重塑基因中观察到 CIMP 簇特异性突变,例如 SWItch/Sucrose Non-Fermentable 和 Chromodomain Helicase DNA-Binding 基因家族。
结直肠癌有 5 个临床和分子上不同的亚组。我们显示 CIMP 与年龄、性别和肿瘤位置之间存在显著关联,并确定基因体甲基化在锯齿状肿瘤进展中的作用。这些数据支持我们最近的发现,即 CIMP 在年轻患者中不常见,并且年轻患者中的 BRAF 突变息肉恶性进展的潜力有限。